It has been prescribed for you because your body has a shortage of carnitine
PlexusDx patients at $189/mo month-to-month, or from $149/mo on the 6-month plan for compounded semaglutide injection often adjust to higher maintenance doses by week 46 as appetite suppression plateaus

Real-world safety data from the FDA Adverse Event Reporting System suggests that Mounjaro may actually have lower pancreatitis risk compared to some other GLP-1 receptor agonists: Mounjaro (tirzepatide): Adjusted ROR 2.74 (suggests the reporting rate is about 2.7 times higher than would be expected if there was no association) Liraglutide (Saxenda): ROR 4.76 (suggests the reporting rate is about 4.8 times higher than expected, making it higher risk than Mounjaro) Semaglutide (Wegovy/Ozempic): ROR 2.04 (suggests the reporting rate is about 2 times higher than expected, slightly lower than Mounjaro) Dulaglutide (Trulicity): ROR 2.01 (suggests the reporting rate is about 2 times higher than expected, slightly lower than Mounjaro) While these numbers may seem complicated, they suggest that Mounjaros pancreatitis risk is comparable to or lower than that of other medications in the same class, with liraglutide showing a notably higher risk signal

Reduced appetite (your brain thinks youve eaten enough)
The nausea lessens as your body gets used to how Ozempic works
Yes, the average Wegovy weight loss of 15% is achieved with the 2.4 mg weekly dose